Beasley Allen in the News

Articles 511 to 520 of 684 .

Vioxx battles could cost Merck up to $18B

| November 5, 2004
Already wounded by the withdrawal of its Vioxx pain reliever from the market, Merck must now contend with hundreds of lawsuits over the drug's side effects.

Lawyers Organizing for Mass Lawsuits over Vioxx

| November 5, 2004
Hundreds of plaintiffs' lawyers who claim that people were injured or killed by the painkiller Vioxx plan to meet next week to lay the groundwork for a nationwide legal assault against the drug's maker, Merck.

Merck Faces Slew Of Vioxx Lawsuits

| November 5, 2004
Already wounded by the withdrawal of its Vioxx pain reliever from the market, Merck & Co. must now contend with hundreds of lawsuits over the drug's side effects.

Merck Faces Slew of Vioxx Suits

CBS News | November 5, 2004
Already wounded by the withdrawal of its Vioxx pain reliever from the market, Merck & Co. must now contend with hundreds of lawsuits over the drug's side effects - lawsuits that threaten to further damage the company's finances and reputation.

Vioxx Battles Could Cost Merck up to $18 Billion

The Associated Press | November 5, 2004
Already wounded by the withdrawal of its Vioxx pain reliever from the market, Merck must now contend with hundreds of lawsuits over the drug's side effects-lawsuits that threaten to further damage the company's finances and reputation.

Lawyers Organizing for Mass Suits Over Vioxx

The New York Times | November 5, 2004
Hundreds of plaintiffs' lawyers who claim that people were injured or killed by the

Merck Faces Huge Fallout Over Vioxx Suits

Forbes | November 4, 2004
Already wounded by the withdrawal of its Vioxx pain reliever from the market, Merck & Co. must now contend with hundreds of lawsuits over the drug's side effects - lawsuits that threaten to further damage the company's finances and reputation. Companies

Merck Stock Tumbles nearly 10 Percent

| November 2, 2004
Merck & Co.'s shares fell nearly 10 percent, to the lowest price in almost nine years, after The Wall Street Journal reported that the drug maker tried for years to stop safety concerns from hurting sales of its blockbuster arthritis drug Vioxx.

Lawyers put pressure on Merck over Vioxx

The Financial Times | November 2, 2004
Plaintiffs' attorneys stepped up pressure on Merck on cases related to its withdrawal of Vioxx, the anti-inflammatory drug, sending the US drugmaker's shares plummeting again.

Merck Falls on report of Secrecy

The Record | November 2, 2004
Shares of Merck & Co. plunged again after a news report suggested the drug maker attempted to keep safety worries from hurting the prospects of Vioxx before the company finally recalled the painkiller.